latanoprostene bunod latanoprostene bunod latanoprostene bunod (trade name vyzulta) is an ophthalmic drug approved in the united states in 2017 for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. it targets the trabecular meshwork directly. latanoprostene bunodclinical datatrade namesvyzultaother namesbol-303259-xahfs/drugs.commultum consumer informationlicense data us dailymed: latanoprostene bunod atc codes01ee06 (who) legal statuslegal status ca: ℞-only us: ℞-only identifiers iupac name 4-nitrooxybutyl (z)-7-cyclopentyl]hept-5-enoate cas number860005-21-6pubchem cid11156438drugbankdb11660chemspider9331546uniii6393o0922keggd10441echa infocard100.251.571 chemical and physical dataformulac27h41no8molar mass507.624 g·mol−13d model (jsmol)interactive image smiles c1(((1o)c/c=c\cccc(=o)occcco(=o))cc(ccc2=cc=cc=c2)o)o inchi inchi=1s/c27h41no8/c29-22(15-14-21-10-4-3-5-11-21)16-17-24-23(25(30)20-26(24)31)12-6-1-2-7-13-27(32)35-18-8-9-19-36-28(33)34/h1,3-6,10-11,22-26,29-31h,2,7-9,12-20h2/b6-1-/t22-,23+,24+,25-,26+/m0/s1key:lovmmubrqufeah-uieazxiasa-n